Business Wire Industry News

Wednesday, December 8, 2021

Devonian Health Group Announces Publication of Article on Potential Use of Thykamine™ in the Treatment of Covid-19 in the International Journal of Noncommunicable Diseases

QUEBEC CITY--(BUSINESS WIRE)--Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, announced today the publication of an article in the peer-reviewed International Journal of Noncommunicable Diseases describing the potential use of Thykamine™ as a therapeutic agent for Covid-19. The article is titled, ‘‘Coronavirus disease 2

Wednesday, December 8, 2021

Cybin Confirms Scientific Advice Meeting with UK Medical and Healthcare Products Regulatory Agency for Lead Candidate CYB003 for the Treatment of Major Depressive Disorder and Alcohol Use Disorder

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics™” is pleased to announce that it has confirmed a scientific advice meeting with the UK Medical and Healthcare Products Regulatory Agency (“MHRA”) for the first quarter of calendar year 2022. This program milestone brings the Company closer toward advancing its lead investigational candidate CYB003 into clinical developm

Tuesday, December 7, 2021

ImmunoPrecise Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2022

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #Deltavariant--IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody discovery and development, today announced that it will host a conference call to discuss its financial results and recent business highlights for second quarter fiscal year 2022 on December 13, 2021, after the close of market. The financial results will be issued in a press release prior to the call. ImmunoPrecise ma

Tuesday, December 7, 2021

Medicago and GSK Announce Positive Phase 3 Efficacy and Safety Results for Adjuvanted Plant-Based COVID-19 Vaccine Candidate

QUEBEC CITY & LONDON--(BUSINESS WIRE)--Medicago, a biopharmaceutical company headquartered in Quebec City, and GlaxoSmithKline (GSK) today announce positive efficacy and safety results from the global Phase 3 placebo-controlled efficacy study of Medicago’s plant-based COVID-19 vaccine candidate in combination with GSK’s pandemic adjuvant, conducted in over 24,000 subjects, adults 18 years and above, across six countries. Vaccine efficacy was demonstrated in an environment dominated by SARS-CoV-

Monday, December 6, 2021

Alpha Cognition Announce Data from Pre-Clinical Study of ALPHA-1062 for Traumatic Brain Injury

VANCOUVER, British Columbia--(BUSINESS WIRE)--Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, is pleased to announce functional data from their ALPHA-1062 intranasal Traumatic Brain Injury (TBI) program. ALPHA-1062 administration significantly, acutely reduced the extent of the functional d

Friday, December 3, 2021

FSD Pharma to Present at the H.C. Wainwright 2nd Annual Psychedelics Virtual Conference on December 6th

TORONTO--(BUSINESS WIRE)---- $HUGE #FSDPharma--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) (“FSD Pharma” or the “Company”), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, announced today that Anthony Durkacz, Interim CEO of FSD Pharma, will present at the H.C. Wainwright 2nd Annual Virtual Psychedelics Conference to be held on December 6, 2021. Mr. Durkacz’s presentation will be available on-demand for conference attendees starting at 7:00 a.m. ET and ac

Thursday, December 2, 2021

Alpha Cognition Appoints Cedric O’Gorman, M.D., MBA as Chief Medical Officer

VANCOUVER, British Columbia--(BUSINESS WIRE)--Alpha Cognition Inc. (TSX-V: ACOG)(OTCQB: ACOGF)(“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, today announced the appointment of Cedric O’Gorman, M.D., as the Company’s Chief Medical Officer. Dr. O’Gorman will lead medical, clinical and regulatory functions in support of the company's clinica

Thursday, December 2, 2021

FSD Pharma Unveils Videos Demonstrating Positive Effects of Lucid-MS in Treating Multiple Sclerosis in Pre-Clinical Models (Mouse Models)

TORONTO--(BUSINESS WIRE)---- $HUGE #FSDPharma--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) (“FSD Pharma” or the “Company”), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, announced today that it is sharing pre-clinical data, supported by an explanatory video, demonstrating the potentially disease-modifying effects of Lucid-MS, the Company’s lead drug candidate for the potential treatment of multiple sclerosis (“MS”), in the animal models of MS. Based on

Thursday, December 2, 2021

Biomind Labs to Participate in the H.C. Wainwright 2nd Annual Psychedelics Conference on December 6, 2021

TORONTO--(BUSINESS WIRE)--Biomind Labs Inc. (“Biomind Labs” or the “Company”) (NEO: BMND) (FSE: 3XI), a leading biotech company in fast-acting psychedelics is pleased to announce that Alejandro Antalich, Chief Executive Officer, and Dr. Draulio Barros de Araujo, Scientific and Clinical Advisor, will participate at the 2nd Annual H.C. Wainwright Psychedelics Conference being held virtually on Monday, December 6, 2021. “The title of the Conference: “Back to the Future: Positioning for the Psyched

Thursday, December 2, 2021

Role of B Cells Induced by IMV’s Lead Compound in Patients with Ovarian Cancer to be Showcased at the ESMO-IO Congress

DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)--IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX™ platform to treat solid and blood cancers, today announced new translational data implicating B cells in the clinical benefit induced by MVP-S treatment in ovarian cancer patients. These data will be showcased at the European Society for Medical Oncology Immuno-Oncology (ESMO-IO) congress, December 8-1

Wednesday, December 1, 2021

Cybin to Present at the Stifel GMP 2nd Annual Future of Healthcare Conference on December 8, 2021

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing “Psychedelics to TherapeuticsTM” is pleased to announce that Doug Drysdale, Cybin’s Chief Executive Officer, will present at the Stifel GMP 2nd Annual Future of Healthcare Conference being held virtually on Wednesday, December 8, 2021. Mr. Drysdale’s presentation will be webcast live on December 8, 2021 at 3:30 p.m. ET. To listen to the event, pleas

Wednesday, December 1, 2021

Back Bay Life Science Advisors Announces Expansion into Canada with Opening of Toronto Office

BOSTON--(BUSINESS WIRE)--Back Bay Life Science Advisors, an international partner for biopharma, medtech and healthtech companies and their investors, announced the opening of its new office in Toronto, Canada, to further support clients and partners located across the global life sciences and healthcare markets. With a strong presence in Boston and Northern Europe, this North American expansion further strengthens Back Bay’s role in developing promising life science communities globally. In ad